D.A. Davidson & Co. Abb Vie Inc. Transaction History

D.A. Davidson & Co.

$11.2 Billion
Q2 2024

A detailed history of D.A. Davidson & Co. transactions in Abb Vie Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 251,378 shares of ABBV stock, worth $49 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares

251,378

Previous 249,448 0.77%

Holding current value

$49 Million

Previous $45.4 Million 5.08%

% of portfolio

0.39%

Previous 0.41%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$154.79 - $180.76 $298,744 - $348,866	1,930 Added 0.77%	251,378 $43.1 Million
Q1 2024 May 13, 2024	SELL	$159.82 - $182.1 $45,548 - $51,898	-285 Reduced 0.11%	249,448 $45.4 Million
Q4 2023 Feb 09, 2024	SELL	$137.6 - $154.97 $596,083 - $671,330	-4,332 Reduced 1.71%	249,733 $38.7 Million
Q3 2023 Nov 08, 2023	BUY	$133.59 - $154.65 $459,015 - $531,377	3,436 Added 1.37%	254,065 $37.9 Million
Q2 2023 Aug 10, 2023	SELL	$132.51 - $164.9 $1.11 Million - $1.38 Million	-8,341 Reduced 3.22%	250,629 $33.8 Million
Q1 2023 Apr 25, 2023	SELL	$144.61 - $166.54 $4.83 Million - $5.56 Million	-33,381 Reduced 11.42%	258,970 $41.3 Million
Q4 2022 Feb 03, 2023	BUY	$138.31 - $165.87 $335,263 - $402,068	2,424 Added 0.84%	292,351 $47.3 Million
Q3 2022 Nov 07, 2022	SELL	$134.21 - $153.93 $1.14 Million - $1.31 Million	-8,523 Reduced 2.86%	289,927 $39.1 Million
Q2 2022 Jul 28, 2022	SELL	$137.62 - $174.96 $1.26 Million - $1.6 Million	-9,121 Reduced 2.97%	298,450 $45.7 Million
Q1 2022 May 12, 2022	SELL	$131.98 - $163.75 $1.5 Million - $1.86 Million	-11,338 Reduced 3.56%	307,571 $49.9 Million
Q4 2021 Jan 31, 2022	SELL	$107.43 - $135.93 $191,762 - $242,635	-1,785 Reduced 0.56%	318,909 $43.2 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $1.63 Million - $1.85 Million	15,357 Added 5.03%	320,694 $34.6 Million
Q2 2021 Aug 10, 2021	BUY	$105.21 - $117.21 $1.39 Million - $1.55 Million	13,200 Added 4.52%	305,337 $34.4 Million
Q1 2021 May 07, 2021	BUY	$102.3 - $112.62 $9.12 Million - $10 Million	89,126 Added 43.9%	292,137 $31.6 Million
Q4 2020 Feb 10, 2021	BUY	$80.49 - $108.67 $462,415 - $624,309	5,745 Added 2.91%	203,011 $21.7 Million
Q3 2020 Nov 02, 2020	SELL	$85.91 - $100.83 $107,559 - $126,239	-1,252 Reduced 0.63%	197,266 $17.3 Million
Q2 2020 Aug 10, 2020	SELL	$73.37 - $98.18 $4.27 Million - $5.71 Million	-58,188 Reduced 22.67%	198,518 $19.5 Million
Q1 2020 May 05, 2020	BUY	$64.5 - $97.79 $1.22 Million - $1.85 Million	18,879 Added 7.94%	256,706 $19.5 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $2.07 Million - $2.59 Million	28,648 Added 13.7%	237,827 $21.1 Million
Q3 2019 Nov 05, 2019	BUY	$62.98 - $75.72 $3.49 Million - $4.19 Million	55,338 Added 35.97%	209,179 $15.8 Million
Q2 2019 Aug 13, 2019	SELL	$65.7 - $83.98 $199,990 - $255,635	-3,044 Reduced 1.94%	153,841 $11.2 Million
Q1 2019 May 13, 2019	SELL	$77.14 - $90.79 $338,721 - $398,658	-4,391 Reduced 2.72%	156,885 $12.9 Million
Q4 2018 Jan 29, 2019	BUY	$77.85 - $96.01 $18,839 - $23,234	242 Added 0.15%	161,276 $14.9 Million
Q3 2018 Nov 13, 2018	SELL	$88.91 - $98.84 $28,717 - $31,925	-323 Reduced 0.2%	161,034 $15.2 Million
Q2 2018 Aug 02, 2018	BUY	$89.78 - $106.23 $586,173 - $693,575	6,529 Added 4.22%	161,357 $15 Million
Q1 2018 May 04, 2018	BUY	$92.01 - $123.21 $135,254 - $181,118	1,470 Added 0.96%	154,828 $14.7 Million
Q4 2017 Feb 08, 2018	BUY	$89.56 - $98.21 $875,628 - $960,199	9,777 Added 6.81%	153,358 $14.8 Million
Q3 2017 Nov 08, 2017	BUY	$69.85 - $89.22 $203,612 - $260,076	2,915 Added 2.07%	143,581 $12.8 Million
Q2 2017 Aug 11, 2017	BUY	N/A	140,666	140,666 $0

Others Institutions Holding ABBV

# of Institutions

3,694

Shares Held

1.27B

Call Options Held

13M

Put Options Held

9.79M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $344B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account